Director/PDMR Shareholding

GlaxoSmithKline PLC 19 December 2007 Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons Following a revaluation of the cash element of the investment held within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and Dr R G Greig on 17 December 2007 of an increase in the notional allocation of Ordinary share ADRs on 14 December 2007 at a price of $53.00 per ADR share:- No. of ADRs Dr R G Greig 2 This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a). Additionally, following the recalculation of the cash element of the notional investment in GSK Ordinary share ADRs under The Plan, the previous increases in the notional allocations of ADRs at a price of $51.25 per ADR share, announced on 2 November 2007, are restated as follows:- No. of ADRs Previous Restated valuation valuation Mr W Louv 6 7 Dr M Slaoui 1 2 Mr D Stout 37 38 Dr D Pulman 15 16 Dr R G Greig 89 88 Following a separate recalculation of the cash element of the notional investment in GSK Ordinary share ADRs under The Plan, the increase in the notional allocation of ADRs to Dr R G Greig announced on 28 November 2007 was 3,279 ADRs at a price of $50.19 per ADR share (not 3,287 ADRs as previously announced). This final restatement is required as a result of a technical calculation of notional ADRs advised to the Company by a third party. S M Bicknell Company Secretary 19 December 2007 This information is provided by RNS The company news service from the London Stock Exchange

Companies

GSK (GSK)
UK 100

Latest directors dealings